SubsidieMeestersBest-in-class canceR dIaGnostic cHip for patient sTratification.
The RUBYchip is a microfluidic liquid biopsy device that isolates and analyzes cancer cells from blood samples, enabling efficient and reliable monitoring of cancer progression.
Projectdetails
Introduction
Through advanced microengineering and nanotechnology, we have developed a proprietary microfluidic-based liquid biopsy device, the RUBYchip (PCT/EP2016/078406). This technology allows for the isolation of all types of CTCs, keeping them viable and enabling the analysis of their phenotypic, genetic, and functional characteristics.
Benefits of RUBYchip
This enables unprecedented frequent monitoring of cancer progression in a minimally invasive and cost-efficient way. Our chip isolates 70% of the very scarce CTCs from a 7.5mL blood sample of a cancer patient in less than 3 hours and without the need for sample preprocessing.
Unique Features
This dramatic improvement in sensitivity compared to competition is enabled by a unique microfilter network embedded in a microfluidic device that separates the CTCs from the healthy cells based on their size and deformability.
Automation and Reproducibility
Furthermore, the RUBYchip enables automation, reducing inter-laboratory and inter-user dependence and ensuring reproducible analysis of CTCs.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.497.880 |
| Totale projectbegroting | € 3.568.401 |
Tijdlijn
| Startdatum | 1-8-2022 |
| Einddatum | 30-4-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- RUBYNANOMED LDApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
INNOVATIVE LIQUID BIOPSY METHOD USING LAB-ON-ACHIP TECHNOLOGY FOR CANCER DIAGNOSIS AND MANAGEMENTJaxBio aims to revolutionize lung cancer diagnosis and treatment with LUMEN, a non-invasive liquid biopsy assay that detects cancer early and predicts treatment response using advanced DNA-chip technology. | EIC Accelerator | € 2.493.000 | 2024 | Details |
The critical shift to single-cell formats in functional analyses of living cellsSamplix is developing Xplore, a cost-effective single-cell analyser and sorter to enhance immune cell analysis, supporting faster development of personalized therapies for serious diseases. | EIC Accelerator | € 2.500.000 | 2023 | Details |
INNOVATIVE LIQUID BIOPSY METHOD USING LAB-ON-ACHIP TECHNOLOGY FOR CANCER DIAGNOSIS AND MANAGEMENT
JaxBio aims to revolutionize lung cancer diagnosis and treatment with LUMEN, a non-invasive liquid biopsy assay that detects cancer early and predicts treatment response using advanced DNA-chip technology.
The critical shift to single-cell formats in functional analyses of living cells
Samplix is developing Xplore, a cost-effective single-cell analyser and sorter to enhance immune cell analysis, supporting faster development of personalized therapies for serious diseases.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC Consolid... | € 1.993.875 | 2023 | Details |
Targeted Microarrays for 5-hydroxymethylcytosine-based Diagnosis of Hematological MalignanciesThis project aims to develop a cost-effective DNA chip for mapping 5-hydroxymethylcytosine (5hmC) to identify cancer biomarkers and improve diagnostic testing accessibility. | ERC Proof of... | € 150.000 | 2022 | Details |
Een polymere microgestructureerde nanowellchip voor de analyse van individuele cellen op basis van microfabricage met behulp van 3D-printtechnologieHet project ontwikkelt betaalbare, op maat gemaakte micro-3D-geprinte chips voor single-cell analyses ter verbetering van kankerdiagnostiek en gepersonaliseerde therapieën. | Mkb-innovati... | € 167.760 | 2023 | Details |
Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritizationValo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates. | EIC Transition | € 2.226.280 | 2023 | Details |
Fast and simple biomarker detection by computational microscopyWe developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics. | ERC Proof of... | € 150.000 | 2024 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Targeted Microarrays for 5-hydroxymethylcytosine-based Diagnosis of Hematological Malignancies
This project aims to develop a cost-effective DNA chip for mapping 5-hydroxymethylcytosine (5hmC) to identify cancer biomarkers and improve diagnostic testing accessibility.
Een polymere microgestructureerde nanowellchip voor de analyse van individuele cellen op basis van microfabricage met behulp van 3D-printtechnologie
Het project ontwikkelt betaalbare, op maat gemaakte micro-3D-geprinte chips voor single-cell analyses ter verbetering van kankerdiagnostiek en gepersonaliseerde therapieën.
Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization
Valo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates.
Fast and simple biomarker detection by computational microscopy
We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.